NCT06672263View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

TQB3911 tablets

TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells.

Trial Locations (5)

100044

Peking University People's Hospital, Beijing

200025

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

310006

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

530021

The First Affiliated Hospital of Guangxi Medical University, Nanning

Unknown

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY